Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
25 studies found for:    (menopause OR postmenopause) [CONDITION ] ((hormone therapy) OR HRT) [TREATMENT ] | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
(menopause OR postmenopause) [CONDITION ] ((hormone therapy) OR HRT) [TREATMENT ] | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder
Condition: Menopausal Syndromes
Interventions: Drug: Tibolone;   Drug: Estradiol & medroxyprogesterone acetate
2 Recruiting Estrogen Diastolic Heart Failure
Condition: Menopause
Interventions: Drug: Estradiol/Norethindrone acetate;   Drug: Placebo
3 Recruiting Efficacy Study of Progesterone Tablet in Post-menopausal Women
Condition: Menopause
Intervention: Drug: Progesterone
4 Recruiting Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women
Condition: Menopause
Interventions: Drug: oral estradiol 0.5 mg;   Drug: oral estradiol 1.0 mg;   Drug: oral progesterone 100 mg
5 Recruiting Females, Aging, Metabolism, and Exercise
Condition: Obesity
Interventions: Drug: GnRH agonist;   Behavioral: Supervised cardiovascular exercise;   Drug: Placebo
6 Recruiting Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
Conditions: Cognitive Impairment;   Executive Dysfunction;   Endothelial Dysfunction;   Cardiovascular Disease
Interventions: Drug: Leuprolide acetate;   Drug: Estradiol;   Drug: Medroxyprogesterone;   Drug: Placebo
7 Recruiting Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women
Condition: Breast Cancer
Intervention:
8 Recruiting Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy
Conditions: Atrophic Vaginitis;   Menopause
Interventions: Device: CO2 fractionated vaginal laser;   Drug: Estrogens, Conjugated (USP)
9 Not yet recruiting Oral Contraceptives as Infertility Treatments for Premature Ovarian Failure
Conditions: Primary Ovarian Insufficiency;   Menopause, Premature
Intervention: Drug: Drospirenone and ethinyl estradiol combination (Yasmin)
10 Recruiting PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline;   Procedure: Diagnostic Imaging: 18F-FES PET/CT - Baseline;   Procedure: Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up
11 Not yet recruiting Sustainability of Vaginal Estrogen Therapy in Postmenopausal Women
Conditions: Atrophy of Vagina;   Postmenopause
Intervention: Drug: Gynoflor
12 Not yet recruiting Postprandial Lipidemia After a Meal With Different Types of Fat, Estrogen Treatment, Age and Gender in Healthy Subjects
Condition: Menopause
Interventions: Drug: Estrogens;   Other: Placebo
13 Not yet recruiting Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy
Conditions: Atrophic Vaginitis;   Menopause;   Vulvovaginal Atrophy
Interventions: Drug: Vaginal progesterone;   Drug: Placebo
14 Recruiting Estrogen Therapy as Prevention in the Progression of Aneurysm (EPPA) Trial
Conditions: Cerebral Aneurysm;   Menopause;   Treatment
Interventions: Drug: Estradiol;   Drug: Placebo
15 Recruiting Transdermal Testosterone Nanoemulsion in Women Libido
Condition: Menopause
Interventions: Drug: Testosterone;   Drug: Placebo
16 Recruiting Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery
Conditions: Estrogen;   Menopause;   Pelvic Floor Disorders;   Surgery
Interventions: Drug: Premarin;   Drug: Vagifem
17 Recruiting Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women
Condition: Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Intervention: Drug: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
18 Recruiting Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women
Condition: Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Intervention: Drug: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
19 Recruiting Tibolone and Placebo in Adjunct to Antidepressant Medication for Women With Menopausal Depression
Condition: Menopausal Depression
Intervention: Drug: Tibolone
20 Not yet recruiting Phase I Clinical Trial of PK, PD and Safety Evaluations of Testosterone Gel 1% for 28 Days in Post-menopausal Women.
Condition: Post-menopausal Period
Intervention: Drug: Testosterone

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.